Skip to main navigation
Oculis Logo Oculis Logo Oculis Logo Oculis Logo Oculis Logo
  • COMPANY
    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE
    • OPTIREACH Technology
    • Antibody Fragment Technology
    • NEUROPROTECTIVE APPROACH FOR EYE DISEASES
    • Publications
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 ACUTE OPTIC NEURITIS
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources
  • COMPANY
    • About Us
    • Executive Team
    • Board of directors
    • Scientific Advisory Board
    • Business Development
    • Contact Us
  • SCIENCE
    • OPTIREACH Technology
    • Antibody Fragment Technology
    • NEUROPROTECTIVE APPROACH FOR EYE DISEASES
    • Publications
  • PIPELINE
    • Overview
    • OCS-01 Diabetic Macular Edema
    • OCS-01 Post Cataract Surgery Inflammation
    • OCS-02 Dry Eye Disease
    • OCS-02 Uveitis
    • OCS-05 ACUTE OPTIC NEURITIS
    • OCS-05 Glaucoma
  • CAREERS
  • INVESTORS & MEDIA
    • Overview
    • Stock Information
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Investor FAQs
    • Investor Resources

News Releases


    Oculis Announces to Present at Upcoming August Investor Conferences
    July 26, 2023
    Oculis Announces to Present at Upcoming August Investor Conferences
    Oculis to Present at OIS Retina Innovation Summit
    July 19, 2023
    Oculis to Present at OIS Retina Innovation Summit
    Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
    June 26, 2023
    Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023
    Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
    June 13, 2023
    Oculis Announces Partial Exercise of Underwriters’ Option to Purchase Additional Ordinary Shares
    Oculis wins the Icelandic Knowledge Award - image
    June 12, 2023
    Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics
    Oculis to Participate in Jefferies Healthcare Conference
    June 1, 2023
    Oculis to Participate in Jefferies Healthcare Conference
    Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
    May 31, 2023
    Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares
    Oculis Announces Upcoming Presentation of Positive Stage 1 Top Line Results from Phase 3 DIAMOND Trial at  Clinical Trials at the Summit (CTS)
    May 31, 2023
    Oculis Announces Upcoming Presentation of Positive Stage 1 Top Line Results from Phase 3 DIAMOND Trial at Clinical Trials at the Summit (CTS)
    Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
    May 30, 2023
    Oculis Announces Launch of Proposed Public Offering of Ordinary Shares
    Oculis to Participate and Present at Upcoming EuDES Meeting
    May 24, 2023
    Oculis to Participate and Present at Upcoming EuDES Meeting
Pagination
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • Next page ›
  • Last page »
Displaying 11 - 20 of 31
Contact us

Oculis Holding AG
Bahnofstrasse 7
6300 Zug
Switzerland

+41 58 810 0182

 

info@oculis.com

Oculis Operations Sàrl
EPFL Innovation Park Building D
1015 Lausanne
Switzerland

+41 21 711 3970

Copyright © 2023 Oculis.

 





    © Oculis – Privacy Policy Terms of Use Cookie Policy

    © L’autreagence 2019 – 2023